X hits on this document

684 views

0 shares

0 downloads

0 comments

14 / 170

10

the discussion involves any other products or fillers not already on the agenda for which

11

the FDA participant has a personal or imputed financial interest, the participants need to

12

exclude themselves from such involvement and their exclusion will be noted for the

13

record.

5

With respect to FDA’s industry representative, we would like to disclose

6

that Dr. Rick Veltri is serving as the non-voting industry representative, acting on behalf

Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com

1

Based on the agenda for today’s meeting all financial interests reported

2

by the Committee members and temporary voting members it has been determined that

3

our interests in firms regulated by the Center for Drug Evaluation and Research present

7

of our regulated industry. Dr. Veltri’s role at this meeting is to represent industry in

8

general and not any one particular company. Dr. Veltri is employed by Schering-Plough.

4

no potential for conflict of interest.

13

9

We would like to remind members and temporary voting members that if

23

meeting is open for public observation, public attendees may not participate, except at the

24

specific request of the panel.

14

15

FDA encourages all the participants to advise the Committee of any

financial relationships that they may have with any firms at issue. Thank you.

16

17

DR. BURMAN: Eric, good morning. We just introduced ourselves and

maybe, would you be kind enough to do that as well?

22

I would like to remind public observers at this meeting that while this

18

19

DR. FELNER: My name is Eric Felner. I’m a Pediatric Endocrinologist

at Emory University.

20

21

DR. BURMAN: Thank you. We will now proceed with our first

presentation from the FDA by Dr. Hylton Joffe.

Document info
Document views684
Page views684
Page last viewedSun Jan 22 23:26:44 UTC 2017
Pages170
Paragraphs7975
Words54271

Comments